Comprehensive Financial Consultants Institutional Inc. Increases Stake in Johnson & Johnson $JNJ

Comprehensive Financial Consultants Institutional Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,460 shares of the company’s stock after acquiring an additional 446 shares during the quarter. Johnson & Johnson comprises about 1.5% of Comprehensive Financial Consultants Institutional Inc.’s portfolio, making the stock its 16th largest position. Comprehensive Financial Consultants Institutional Inc.’s holdings in Johnson & Johnson were worth $4,500,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Asset Planning Services Inc. LA ADV raised its stake in shares of Johnson & Johnson by 1.0% in the second quarter. Asset Planning Services Inc. LA ADV now owns 37,639 shares of the company’s stock valued at $5,749,000 after acquiring an additional 365 shares during the period. Investors Asset Management of Georgia Inc. GA ADV raised its stake in shares of Johnson & Johnson by 1.3% in the second quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 9,126 shares of the company’s stock valued at $1,394,000 after acquiring an additional 116 shares during the period. AWM Capital LLC raised its stake in shares of Johnson & Johnson by 3.3% in the second quarter. AWM Capital LLC now owns 3,222 shares of the company’s stock valued at $492,000 after acquiring an additional 103 shares during the period. Autumn Glory Partners LLC raised its stake in shares of Johnson & Johnson by 6.9% in the second quarter. Autumn Glory Partners LLC now owns 23,835 shares of the company’s stock valued at $3,641,000 after acquiring an additional 1,548 shares during the period. Finally, PUREfi Wealth LLC raised its stake in shares of Johnson & Johnson by 21.5% in the second quarter. PUREfi Wealth LLC now owns 8,548 shares of the company’s stock valued at $1,306,000 after acquiring an additional 1,514 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on JNJ shares. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Citigroup raised their price target on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $189.88.

Johnson & Johnson Stock Up 0.4%

Shares of Johnson & Johnson stock opened at $188.95 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.92. The firm’s 50-day moving average is $177.04 and its two-hundred day moving average is $163.18. The stock has a market cap of $455.06 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the prior year, the business earned $2.82 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.